← Back to Home

AI-designed proteins create RNA carriers that achieve gene editing in pig muscle

Selected from more than 100 synthetic structures, STV-C8 offers a new option for RNA delivery. Cell and animal experiments have provided preliminary evidence, but which cells it reaches and whether it can be used safely in humans remain the next hurdles.

By SURL BioNews

For RNA therapies to work, the molecules first need to reach cells intact. Whether the aim is to make cells produce therapeutic proteins or initiate gene editing, delivery can limit effectiveness. A German research team combined natural protein components with scaffolds designed using generative AI to create synthetic RNA carriers, then tested their function in cells, mice and a pig.

The study, published in *Nature*, was a collaboration involving Helmholtz Munich, the Technical University of Munich and other institutions. The team assembled more than 100 “synthetic transport vehicles” (STVs) of different sizes and shapes from scratch, with STV-C8 performing best. AI’s specific task was to design protein structures that support functional components; some of the effective geometries differed markedly from natural viral shells.

According to the research institutions, STV-C8 delivered RNA more efficiently in cell culture experiments than the virus-like particles and lipid nanoparticles tested in the study. It also required less RNA to achieve similar protein production. However, this advantage depends on the conditions of the comparison and cannot be directly extrapolated to mean that it outperforms all existing delivery systems in humans.

The carriers can also be adapted to different tasks. The paper’s abstract, as listed by the Technical University of Munich, states that the researchers added computationally designed peptides capable of binding to specific targets to alter which cells the carriers preferentially enter, and tested RNA cargo with therapeutic uses. This takes protein design beyond shaping structures toward adjusting biological function; precise targeting of cells within the body still requires further validation.

The animal experiments demonstrated two different use scenarios. After mice received intravenous injections of STV-C8, expression from the delivered RNA was observed mainly in the lungs, and the team tracked its distribution in the body using imaging at near-single-cell resolution. The research institutions said no immune or toxic side effects were detected in the reported experiments. This remains an observation under specific experimental conditions and is not sufficient to establish safety in humans or with long-term use.

Another test focused on a gene-editing strategy for Duchenne muscular dystrophy. The research included patient-derived cells, and STV-C8 loaded with components of the CRISPR/Cas9 system was injected into the muscle of one pig, successfully removing a disease-associated sequence from the dystrophin gene. This provides proof of concept for local delivery and editing, but does not yet establish that it can improve patients’ muscle strength or effectively deliver editing tools to muscles throughout the body.

STV-C8 remains an experimental platform. The team plans to establish a spin-off company to advance the technology. Before it can move toward medical applications, however, a clearer understanding is needed of where the carriers go in the body and how to deliver RNA into specified cells. The study expands the range of protein structures available for RNA carriers while leaving a concrete question for the next step: how to translate delivery efficiency in the laboratory into controllable, verifiable therapeutic effects.

References

  1. Phys.org
  2. Helmholtz Munich
  3. Technical University of Munich